March 12, 2018 / 9:04 PM / 2 months ago

BRIEF-Vascepa® Showed Reductions In Potentially Atherogenic Lipids And Inflammatory Markers In Patients

March 12 (Reuters) - Amarin Corporation Plc:

* VASCEPA® (ICOSAPENT ETHYL) SHOWED REDUCTIONS IN POTENTIALLY ATHEROGENIC LIPIDS AND INFLAMMATORY MARKERS IN PATIENTS WITH PERSISTENT HIGH TRIGLYCERIDES AND ELEVATED HIGH-SENSITIVITY C-REACTIVE PROTEIN (HSCRP) Source text for Eikon: Further company coverage: (Reuters.Brief@thomsonreuters.com)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below